Aprea Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APRE research report →
Price Chart
About the company
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways.
- CEO
- Oren Gilad
- IPO
- 2019
- Employees
- 8
- HQ
- Boston, PA, US
Get TickerSpark's AI analysis on APRE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.25M
- P/E
- -0.33
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.36
- EV/EBITDA
- 2.39
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -44.26%
- ROIC
- -43.86%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-13,233,836
- Net Income
- $-12,599,569+2.8%
- EPS
- $-1.93+17.9%
- OCF Growth
- +4.9%
- FCF Growth
- +5.0%
- 52W High
- $1.49
- 52W Low
- $0.20
- 50D MA
- $0.59
- 200D MA
- $0.73
- Beta
- 1.69
- RSI (14)
- 25
- Avg Volume
- 388.67K
No earnings-call transcripts are available for APRE yet.
- Free Float
- 91.0%
- Shares Outstanding
- 14.19M
- Float Shares
- 12.92M
of shares held by institutions
28 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Aigh Capital Management LLC | 1.02M | 0 |
| Soleus Capital Management, L.P. | 1.00M | ▲ 1.00M |
| Vestal Point Capital, LP | 350.00K | 0 |
| Sphera Funds Management Ltd. | 270.00K | 0 |
| Nantahala Capital Management, LLC | 205.76K | 0 |
| Renaissance Technologies LLC | 99.60K | ▼ 6.20K |
| Geode Capital Management, LLC | 74.55K | ▼ 320 |
| Citadel Advisors LLC | 58.60K | ▲ 58.60K |
| Vanguard Group Inc | 58.09K | ▼ 100.15K |
| Vanguard Capital Management LLC | 49.21K | ▲ 26.33K |
| Bnp Paribas Financial Markets | 46.21K | ▲ 1.00K |
| Vanguard Fiduciary Trust Co | 38.46K | 0 |
Held by 6 ETFs
Biggest fund positions in APRE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | Grissinger Michael | other | 12,555 |
| Jun 16, 26 | Grissinger Michael | other | 3,135 |
| Jun 16, 26 | Gruia Gabriela | other | 12,555 |
| Jun 16, 26 | Gruia Gabriela | other | 3,135 |
| Jun 16, 26 | Peters Richard | other | 12,555 |
| Jun 16, 26 | Peters Richard | other | 3,135 |
| Jun 16, 26 | HENNEMAN JOHN B III | other | 3,135 |
| Jun 16, 26 | HENNEMAN JOHN B III | other | 12,555 |
| Jun 16, 26 | BIZZARI JEAN-PIERRE | other | 12,555 |
| Jun 16, 26 | BIZZARI JEAN-PIERRE | other | 3,135 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our APRE coverage
Recent articles, reports, and earnings notes.
Want a deeper read on APRE?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona
globenewswire.com · Nov 20
Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock Has Consensus Price Target of $2.80 According to Brokerages
defenseworld.net · Nov 11
Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
globenewswire.com · Nov 5
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
globenewswire.com · Nov 4
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
globenewswire.com · Oct 16
Aprea Therapeutics to Present at October Conferences
globenewswire.com · Oct 5
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
globenewswire.com · Sep 22
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com · Sep 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
